Source: International Congress 2016 – Cell therapy for ARDS and sepsis
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
Raquel Guillamat-Prats (Barcelona, Spain). Type II pneumocyte transplantation in ARDS. International Congress 2016 – Cell therapy for ARDS and sepsis

Member's Comments

No comment yet.

Related content which might interest you: Evidence of type II pneumocyte apoptosis in the murine model of Hermansky-Pudlak-syndrome associated interstitial pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Pulmonary function and exercise tolerance in glycogenosis type II (GSDII) Source: Annual Congress 2011 - Monitoring with lung function tests in airway diseases Year: 2011 The role of cell lines in modelling the type II pneumocyte in interstitial lung disease Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease Year: 2020 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Transplant of alveolar type II cells restore pulmonary surfactant in lung fibrosis Source: Annual Congress 2010 - Stem cells and growth factors in lung injury Year: 2010 Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010 Aging causes alveolar epithelial type II cell dysfunction in acute lung injury Source: ERS Lung Science Conference 2020 Year: 2020 Type I and III collagen protein precursors in the airways of smokers and COPD-patients Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 Proliferation of alveolar type II pneumocytes is stimulated by Jagged-1 in vitro Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012 Restrictive lung disfunction in metabolic syndrome and type II diabetes Source: Eur Respir J 2006; 28: Suppl. 50, 73s Year: 2006 Longitudinal bronchoscopy findings in children with mucopolysaccharidosis II (MPS II) Source: Virtual Congress 2020 – From the bronchoscope to the clinic: paediatric bronchology at a glance Year: 2020 Lipid peroxidation in cultured rat type II pneumocytes Source: Eur Respir J 2001; 18: Suppl. 33, 79s Year: 2001 Using induced pluripotent stem cells to study the type II pneumocyte Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease Year: 2020 Imbalance of glutathione metabolism in type II pneumocytes after NO2 induced acute and chronic lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 108s Year: 2004 Cell therapy for the treatment of acute lung injury: Alveolar type II cells or mesenchymal stem cells? Source: International Congress 2016 – Novel insights into alveolar and bronchial epithelial cell injury and repair Year: 2016 Effect of alveolar type II cells in acute lung injury model Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury Year: 2015 Respiratory function in stage II pulmonary sarcoidosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 385s Year: 2001 Late Breaking Abstract - Aging impairs alveolar epithelial type II cell function in acute lung injury Source: International Congress 2019 – Cellular metabolism and immune senescence in lung pathology Year: 2019 Changes in lipid metabolism in mucopolysaccharidosis (MPS) IIIA mouse lung tissue and pulmonary surfactant Source: International Congress 2017 – New insights into pathogenesis of lung disease  Year: 2017